← All countries · Eastern Mediterranean
99%
MCV1
2025 · WHO/UNICEF estimate
98%
DTP3
2025 · WHO/UNICEF estimate
99%
IPV complete
2025 · WHO/UNICEF estimate
98%
HepB3
2025 · WHO/UNICEF estimate
7
Measles cases
2025 reported
15
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 100%2025 · Administrative (country-reported) | 100% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 99%2025 · WHO/UNICEF estimate | 99.2% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 98%2025 · WHO/UNICEF estimate | 97.7% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 99%2025 · WHO/UNICEF estimate | 99.2% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 99%2025 · WHO/UNICEF estimate | 100% | C · weak | |
| MCV1First dose of measles-containing vaccine | 99%2025 · WHO/UNICEF estimate | 100% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 99%2025 · WHO/UNICEF estimate | 100% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 99%2025 · WHO/UNICEF estimate | 100% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 98%2025 · WHO/UNICEF estimate | 97.7% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 99%2025 · WHO/UNICEF estimate | 98.9% | A · strong | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 98%2025 · WHO/UNICEF estimate | 97.7% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 100.0%2025 · Administrative (country-reported) | 100.0% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 99%2025 · WHO/UNICEF estimate | 99.0% | A · strong | |
| RotaCRotavirus vaccine, complete series | 97%2025 · WHO/UNICEF estimate | 95.9% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | 100%2005 · Administrative (country-reported) | 100% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 100%2024 · WHO/UNICEF estimate | 98.2% | B · good | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 71%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 61%2025 · WHO/UNICEF estimate | — | too few points | D · poor |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 67%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 72025 | 4.3per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 172025 | 10.3per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 152025 | 9.1per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Japanese encephalitis all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Invasive meningococcal disease all countries · vaccine evidence | 22025 | 1.2per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 392025 | 23.7per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (92 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | Risk group(s) | Infants born to parents (or other household close contact) originally from TB endemic areas and with current smears positive of pulmonary TB |
| CHOLERACholera vaccine | 1 | Risk group(s) | Given in certain emergency situations for relief workers (military workers travelling to at risk countries) | |
| CHOLERACholera vaccine | 1 | Travellers | Given in certain emergency situations for relief workers (military workers travelling to at risk countries) | |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 1 | M2 | Risk group(s) | Children with contraindications or allergic to Pertussis component of the vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 2 | M4 | Risk group(s) | Children with contraindications or allergic to Pertussis component of the vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 3 | M6 | Risk group(s) | Children with contraindications or allergic to Pertussis component of the vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 4 | M18 | Risk group(s) | Children with contraindications or allergic to Pertussis component of the vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | Y4 | Risk group(s) | Children with contraindications or allergic to Pertussis component of the vaccine |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | Routine childhood vaccine given at age of 2 and 4 months and recently added for 6 months (since September 2025) |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4 | General/routine | Routine childhood vaccine given at age of 2 and 4 months and recently added for 6 months (since September 2025) |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M6 | General/routine | Routine childhood vaccine given at age of 2 and 4 months and recently added for 6 months (since September 2025) |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y4-Y5 | General/routine | Routine childhood vaccine given to children at age of 4-5 years (preschool entry) |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 4 | M18 | General/routine | Routine childhood vaccine given at age of 6 months and at the age of 18 months |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Risk group(s) | High risk groups, certain occupations at risk, travellers | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Travellers | High risk groups, certain occupations at risk, travellers | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | Y12 | Catch-up children | Completion of 2 doses of HepA vaccine checked for school students at 12 and 13 years as last school catch-up campaign done in 2016/17 academic year |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | M15 | General/routine | and completion of 2 doses of HepA vaccine checked for school students at 12 and 13 years as last school catch-up campaign done in 2016/17 academic year |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | Y13 | Catch-up children | Completion of 2 doses of HepA vaccine checked for school students at 12 and 13 years as last school catch-up campaign done in 2016/17 academic year |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | Y2 | General/routine | and completion of 2 doses of HepA vaccine checked for school students at 12 and 13 years as last school catch-up campaign done in 2016/17 academic year |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Health workers | High risk groups, certain occupations at risk including HCW, college students | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | High risk groups, certain occupations at risk including HCW, college students | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 5 | Y5 | Risk group(s) | Given as single dose for >5 years children with sickle cell disease, anatomical and/or surgical asplenia, post bone marrow transplant, certain cancer after finishing treatment |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y12-Y13 | HPV administered to females and males | Started Administration of the vaccine to target group (boys and girls aged 12-13 years) as part of school vaccination campaign since October 2023. In addition, the vaccine is also available in the private sector for people requesting it. Expansion of target group to include certain high risk population started since 2024 |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y10-Y45 | Risk group(s) | Recommended for special risk groups: People with multiple sexual partners. People with immunocompromising conditions: ▪ Primary or secondary immunodeficiencies (complete or partial deficiencies of B-lymphocyte antibody or T-lymphocytes) ▪ HIV infection ▪ Malignancy ▪ Organ transplantation ▪ Significant immunosuppressive therapy ▪ People with asplenia or hyposalenia |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6-M12 | HPV administered to females and males | Started Administration of the vaccine to target group (boys and girls aged 12-13 years) as part of school vaccination campaign since October 2023. In addition, the vaccine is also available in the private sector for people requesting it. Expansion of target group to include certain high risk population started since 2024 |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M2 | Risk group(s) | Recommended for special risk groups: People with multiple sexual partners. People with immunocompromising conditions: ▪ Primary or secondary immunodeficiencies (complete or partial deficiencies of B-lymphocyte antibody or T-lymphocytes) ▪ HIV infection ▪ Malignancy ▪ Organ transplantation ▪ Significant immunosuppressive therapy ▪ People with asplenia or hyposalenia |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 3 | +M6 | Risk group(s) | Recommended for special risk groups: People with multiple sexual partners. People with immunocompromising conditions: ▪ Primary or secondary immunodeficiencies (complete or partial deficiencies of B-lymphocyte antibody or T-lymphocytes) ▪ HIV infection ▪ Malignancy ▪ Organ transplantation ▪ Significant immunosuppressive therapy ▪ People with asplenia or hyposalenia |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y50 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | <=Y9 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | Health workers | Immunocompromised and their households. IPV vaccine used in the campaign to cover children without document of two doses of IPV after the year of switch to bivalent OPV2016 and also to HCWs. | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | Risk group(s) | Immunocompromised and their households. IPV vaccine used in the campaign to cover children without document of two doses of IPV after the year of switch to bivalent OPV2016 and also to HCWs. |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | Risk group(s) | Immunocompromised and their households. IPV vaccine used in the campaign to cover children without document of two doses of IPV after the year of switch to bivalent OPV2016 and also to HCWs. |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | Risk group(s) | Immunocompromised and their households. IPV vaccine used in the campaign to cover children without document of two doses of IPV after the year of switch to bivalent OPV2016 and also to HCWs. |
| IPVIPV (Inactivated polio vaccine) | 4 | M18 | Risk group(s) | Immunocompromised and their households. IPV vaccine used in the campaign to cover children without document of two doses of IPV after the year of switch to bivalent OPV2016 and also to HCWs. |
| IPVIPV (Inactivated polio vaccine) | 5 | Y5 | Risk group(s) | Immunocompromised and their households. IPV vaccine used in the campaign to cover children without document of two doses of IPV after the year of switch to bivalent OPV2016 and also to HCWs. |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Y2 | General/routine | Routine childhood vaccine. |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Health workers | Given to high risk groups, HCWs and to travelers to Holly places, meningitis belt countries and countries reporting outbreak | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Risk group(s) | Given to high risk groups, HCWs and to travelers to Holly places, meningitis belt countries and countries reporting outbreak | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Travellers | Given to high risk groups, HCWs and to travelers to Holly places, meningitis belt countries and countries reporting outbreak | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Catch-up children | Given for non-immune women at reproductive age group discovered during premarital counselling, postnatally for non-immune women discovered during antenatal screening, those discovered during preschool screening (without 2 valid MMR doses), if cases identified in a residency blocks, travellers to endemic countries and Hajj Pilgrims, healthcare workers. MMR campiagn to ensure completion of 2 doses of MMR vaccine is conducted to school students in some private and government schools. | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | Routine childhood vaccine, given at the age of 12 and 18 months. |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Health workers | Given for non-immune women at reproductive age group discovered during premarital counselling, postnatally for non-immune women discovered during antenatal screening, those discovered during preschool screening (without 2 valid MMR doses), if cases identified in a residency blocks, travellers to endemic countries and Hajj Pilgrims, healthcare workers. MMR campiagn to ensure completion of 2 doses of MMR vaccine is conducted to school students in some private and government schools. | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Risk group(s) | Given for non-immune women at reproductive age group discovered during premarital counselling, postnatally for non-immune women discovered during antenatal screening, those discovered during preschool screening (without 2 valid MMR doses), if cases identified in a residency blocks, travellers to endemic countries and Hajj Pilgrims, healthcare workers. MMR campiagn to ensure completion of 2 doses of MMR vaccine is conducted to school students in some private and government schools. | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Travellers | Given for non-immune women at reproductive age group discovered during premarital counselling, postnatally for non-immune women discovered during antenatal screening, those discovered during preschool screening (without 2 valid MMR doses), if cases identified in a residency blocks, travellers to endemic countries and Hajj Pilgrims, healthcare workers. MMR campiagn to ensure completion of 2 doses of MMR vaccine is conducted to school students in some private and government schools. | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | Routine childhood vaccine, given at the age of 12 and 18 months. |
| OPVOPV (Oral polio vaccine) | 1 | Travellers | Travellers to polio endemic countries | |
| OPVOPV (Oral polio vaccine) | 2 | M4 | General/routine | Routine childhood vaccine and also provided to travellers to polio endemic countries |
| OPVOPV (Oral polio vaccine) | 3 | M6 | General/routine | Routine childhood vaccine and also provided to travellers to polio endemic countries |
| OPVOPV (Oral polio vaccine) | 4 | M18 | General/routine | Routine childhood vaccine and also provided to travellers to polio endemic countries |
| OPVOPV (Oral polio vaccine) | 5 | Y5 | General/routine | Routine childhood vaccine and also provided to travellers to polio endemic countries |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | >=Y50 | Adults | A single dose for adults at the age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M2 | General/routine | Routine childhood vaccine given at 2 months, 4 months of age and the last dose (Booster) at 15 months. Additional dose is given at 6 months of age for certain high risk group. A single dose for adults at the age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Y5-Y50 | Risk group(s) | A single dose for adults at the age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M4 | General/routine | Routine childhood vaccine given at 2 months, 4 months of age and the last dose (Booster) at 15 months. Additional dose is given at 6 months of age for certain high risk group. A single dose for adults at the age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M15 | General/routine | Routine childhood vaccine given at 2 months, 4 months of age and the last dose (Booster) at 15 months. Additional dose is given at 6 months of age for certain high risk group. A single dose for adults at the age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M6 | Risk group(s) | Routine childhood vaccine given at 2 months, 4 months of age and the last dose (Booster) at 15 months. Additional dose is given at 6 months of age for certain high risk group. |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | >=Y65 | Adults | Routine vaccine for those at age of 65 years and above. Also, given to high risk groups from age of 2 years and above as a single dose and for certain risk categories revaccination dose given after 5 years. |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | >=Y2 | Risk group(s) | Routine vaccine for those at age of 65 years and above. Also, given to high risk groups from age of 2 years and above as a single dose and for certain risk categories revaccination dose given after 5 years. for certain risk categories revaccination dose after 5 years |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 2 | +Y5 | Risk group(s) | Routine vaccine for those at age of 65 years and above. Also, given to high risk groups from age of 2 years and above as a single dose and for certain risk categories revaccination dose given after 5 years. for certain risk categories revaccination dose after 5 years |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | Routine childhood vaccine |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | Routine childhood vaccine |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | >=Y75 | Adults | Given to all adults ages 75 and older and for adults ages 50–74 with increased risk of severe RSV disease. |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Y50-Y74 | Risk group(s) | Given to all adults ages 75 and older and for adults ages 50–74 with increased risk of severe RSV disease. |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | >Y65 | Adults | Given to older individuals > 65 years, others at-risk groups and single dose in each pregnancy to be administered at 27 to 36 weeks. in addition to one dose for Health Care workers |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Health workers | Given to older individuals > 65 years, others at-risk groups and single dose in each pregnancy to be administered at 27 to 36 weeks. in addition to one dose for Health Care workers | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Given to older individuals > 65 years, others at-risk groups and single dose in each pregnancy to be administered at 27 to 36 weeks. in addition to one dose for Health Care workers | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Risk group(s) | Given to older individuals > 65 years, others at-risk groups and single dose in each pregnancy to be administered at 27 to 36 weeks. in addition to one dose for Health Care workers | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y13 | General/routine | Students at schools |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Pregnant women | Pregnant women, in case of injury, certain occupations at risk and others at risk of exposure | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Risk group(s) | Pregnant women, in case of injury, certain occupations at risk and others at risk of exposure | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | >=Y7 | Catch-up children | The vaccine is administered to defaulters children > 7 years of age, if they miss any of the routine doses of the TD containing vaccine. |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | >=Y2 | Risk group(s) | Travellers, certain at risk groups |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | >=Y2 | Travellers | Travellers, certain at risk groups |
| VARICELLAVaricella vaccine | 1 | Y1 | General/routine | Routine childhood vaccine given at one year and three years of age. |
| VARICELLAVaricella vaccine | 1 | Health workers | Given to high risk groups including HCW at direct patient care, household of oncology patient and others | |
| VARICELLAVaricella vaccine | 1 | Risk group(s) | Given to high risk groups including HCW at direct patient care, household of oncology patient and others | |
| VARICELLAVaricella vaccine | 2 | Y3 | General/routine | Routine childhood vaccine given at one year and three years of age. |
| YFYF (Yellow fever) vaccine | 1 | Travellers | Travellers to YF endemic areas | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | >=Y50 | Adults | Given as 2 doses to all adults aged 50 years and older and adults aged 19 years and older with weakened immune systems due to disease or therapy. Also given to patients with chronic conditions at increased risk for severe herpes zoster. |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | >=Y19 | Risk group(s) | Given as 2 doses to all adults aged 50 years and older and adults aged 19 years and older with weakened immune systems due to disease or therapy. Also given to patients with chronic conditions at increased risk for severe herpes zoster. |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | >=Y50 | Adults | Given as 2 doses to all adults aged 50 years and older and adults aged 19 years and older with weakened immune systems due to disease or therapy. Also given to patients with chronic conditions at increased risk for severe herpes zoster. |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | >=Y19 | Risk group(s) | Given as 2 doses to all adults aged 50 years and older and adults aged 19 years and older with weakened immune systems due to disease or therapy. Also given to patients with chronic conditions at increased risk for severe herpes zoster. |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.